Johnson & Johnson has agreed to pay $2.2 billion to settle probes by the U.S. government of its marketing of Risperdal and other medications, the second-largest settlement of its kind in history. Additional cases with individual states are ongoing, for which J&J is setting aside an additional $600 million.
Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.
Mad in America has made some changes to the commenting process. You no longer need to login or create an account on our site to comment. The only information needed is your name, email and comment text. Comments made with an account prior to this change will remain visible on the site.